Research map: Efficacy Measures Used in Alzheimer Disease Clinical Trials Between 2015 and 2025

Back to the article

Papers in this map

  1. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews · Matthew James Page · 2021 · 106363 citations · Cited by this paper
  2. Clinical Trial Outcomes in the Alzheimer's Disease Spectrum · Raymond Scott Turner · 2026 · Cites this paper
  3. Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes · Dror Shir · 2026 · 1 citation · Related
  4. Lecanemab in Early Alzheimer’s Disease · Christopher H. van Dyck · 2022 · 5709 citations · Cited by this paper
  5. Mechanism-Based Therapy With Ampreloxetine for Neurogenic Orthostatic Hypotension in Multiple System Atrophy · 2026 · Related
  6. Donanemab in Early Symptomatic Alzheimer Disease · John Randall Sims · 2023 · 2897 citations · Cited by this paper
  7. Convulsions, Palsy, and the Spanish Inquisition · 2026 · Related
  8. Alzheimer's disease drug development pipeline: 2019 · Jeffrey L. Cummings · 2019 · 782 citations · Cited by this paper
  9. Natural History of Adult-Onset Myotonic Dystrophy Type 1 · 2026 · Related
  10. Alzheimer's disease drug development pipeline: 2018 · Jeffrey L. Cummings · 2018 · 731 citations · Cited by this paper
  11. Rate of Autoimmune Diseases in the 10 Years Preceding Myasthenia Gravis Diagnosis · 2026 · Related
  12. Alzheimer's disease drug development pipeline: 2022 · Jeffrey L. Cummings · 2022 · 690 citations · Cited by this paper
  13. Child Neurology: Early-Onset, Rapidly Progressive, and Refractory DYT- TOR1A Status Dystonicus · 2026 · Related
  14. Alzheimer's disease drug development pipeline: 2020 · Jeffrey L. Cummings · 2020 · 568 citations · Cited by this paper
  15. Teaching NeuroImage: Utility of Arterial Spin Labeling in Detecting Occult Micro-AVM in Angiogram-Negative Acute ICH · 2026 · Related
  16. Alzheimer's disease drug development pipeline: 2026 · Jeffrey L. Cummings · 2025 · 554 citations · Cited by this paper
  17. Antiseizure Medication Dosing Strategy During Pregnancy and Early Postpartum in Women With Epilepsy in MONEAD · 2026 · Related
  18. Alzheimer's disease drug development pipeline: 2021 · Jeffrey L. Cummings · 2021 · 548 citations · Cited by this paper
  19. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019 · David S. Knopman · 2020 · 545 citations · Cited by this paper
  20. Alzheimer's disease drug development pipeline: 2023 · Jeffrey L. Cummings · 2023 · 491 citations · Cited by this paper
  21. Developing the ATX(N) classification for use across the Alzheimer disease continuum · Harald Juergen Hampel · 2021 · 329 citations · Cited by this paper
  22. Alzheimer's disease drug development pipeline: 2024 · Jeffrey L. Cummings · 2024 · 323 citations · Cited by this paper
  23. Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria · Sanne Franzen · 2021 · 146 citations · Cited by this paper
  24. Outcomes measures in a decade of dementia and mild cognitive impairment trials · Jennifer Kirsty Harrison · 2016 · 104 citations · Cited by this paper
  25. Lecanemab and Donanemab as Therapies for Alzheimer's Disease: An Illustrated Perspective on the Data · Alberto J. Espay · 2024 · 94 citations · Cited by this paper
  26. Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease · Roos J. Jutten · 2022 · 91 citations · Cited by this paper
  27. Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease · Sharon Cohen · 2022 · 74 citations · Cited by this paper
  28. Assessing quality of life in Alzheimer's disease: Implications for clinical trials · Kristin Kahle‐Wrobleski · 2016 · 70 citations · Cited by this paper
  29. Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions · Pei‐Jung Lin · 2019 · 69 citations · Cited by this paper
  30. Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for primary care · Alireza Atri · 2024 · 66 citations · Cited by this paper
  31. Heterogeneity of outcome measures in depression trials and the relevance of the content of outcome measures to patients: a systematic review · Christopher Veal · 2024 · 49 citations · Cited by this paper
  32. Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments · Joshua David Wallach · 2024 · 46 citations · Cited by this paper
  33. Systematic scoping review identifies heterogeneity in outcomes measured in adolescent depression clinical trials · Emma J. Mew · 2020 · 42 citations · Cited by this paper
  34. Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit · Poul Flemming Høilund‐Carlsen · 2024 · 39 citations · Cited by this paper
  35. The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond · Rawan M. Tarawneh · 2024 · 38 citations · Cited by this paper
  36. Outcome measures for Alzheimer's disease: A global inter‐societal Delphi consensus · Tim S. Ellison · 2023 · 28 citations · Cited by this paper
  37. Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease · Ming Lu · 2025 · 28 citations · Cited by this paper
  38. Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease · Marieke J. H. J. Dekker · 2019 · 17 citations · Cited by this paper
  39. Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials · Luke E. Stoeckel · 2025 · 14 citations · Cited by this paper

Source: OpenAlex (CC0)